[A case of facial nerve palsy induced by nab-paclitaxel]

Gan To Kagaku Ryoho. 2013 Nov;40(12):2375-7.
[Article in Japanese]

Abstract

The patient was a 60-year-old woman who underwent total mastectomy and axillary lymph node dissection for right breast cancer. She was treated with adjuvant chemotherapy( epirubicin plus cyclophosphamide[EC]and paclitaxel), hormone therapy, and radiation therapy. Multiple lung, lymph node, and bone metastases were detected after 4 years. The patient subsequently received nab-paclitaxel (nabPTX, 260 mg/m2, triweekly) and zoledronate therapy. Ptosis of her right eyebrow and the right angle of her mouth were observed after 8 courses of nabPTX, and peripheral right facial nerve palsy was diagnosed. She underwent rehabilitation, and facial nerve palsy improved after 9 months. Peripheral facial nerve palsy is a very rare adverse event of nabPTX. This is the first case report of peripheral facial nerve paralysis associated with nab- PTX.

Publication types

  • Case Reports

MeSH terms

  • Albumins / administration & dosage
  • Albumins / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Diphosphonates / administration & dosage
  • Facial Paralysis / chemically induced*
  • Facial Paralysis / rehabilitation
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects*
  • Zoledronic Acid

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid
  • Paclitaxel